CPG on ADHD

More documents

Recommendations

Info

functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006Oct;16(5): 599-610.331. Troost PW, Steenhuis MP, Tuynman-Qua HG, Kalverdijk LJ, Buitelaar JK, Minderaa RB,et al. Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children withPervasive Developmental Disorders: A Pilot Study. J Child Adolesc Psychopharmacology.2006 Oct;16(5):611-9.332. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The TexasChildren’s Medication Algorithm Project: revision of the algorithm for pharmacotherapyof attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006Jun;45(6):642-57.333. Sumner CS, Donnelly C, Lopez FA, Sutton V, Bakken R, Paczkowski M, et al. Atomoxetinetreatment for pediatric patients with ADHD and comorbid anxiety. Presented at: AnnualMeeting of the American Psychiatric Association. 2005.334. Bangs ME, Emslie GJ, Spencer T, Ramsey Jl, Detke HC, Allen AJ, et al. A study of atomoxetinein adolescents with ADHD and comorbid depression. 2005.335. McClellan J, Kowatch RA, Findling RL. Practice Parameter for the Assessmentand Treatmentof Children and Adolescents With Bipolar Disorder. J Am Acad Child Adolesc Psychiatry.2007;46(1):107-125.336. Consoli A, Bouzamondo A, Guile JM, Lechat P, Cohen D. Comorbidity with ADHD decreasesresponse to pharmacotherapy in children and adolescents with acute mania: evidencefrom a metaanalysis. Can J Psychiatry. 2007 May;52(5):323-8.337. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatmentguidelines for children and adolescents with bipolar disorder. J Am Acad Child AdolescPsychiatry. 2005 Mar;44(3):213-35.338. State RC, Frye MA, Altshuler LL. Chart review of the impact of attention-deficit/hyperactivitydisorder comorbidity on respondse to lithium of divalproex sodium in adolescent mania.J Clin Psychiatry. 2004;65:1057-63.339. Biederman J, Mick E, Prince J, Bostic JQ, Wilens TE, Spencer T, et al. Systematic chart reviewof the pharmacologic treatment of comorbid attention deficit hyperactivity disorder inyouth with bipolar disorder. J Child Adolesc Psychopharmacology. 1999 Dec;9(4):247-56.340. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literatureand treatment guidelines. J Atten Disord. 2008 Sep;12(2):115-25.341. Upadhyaya HP. Managing attention-deficit/hyperactivity disorder in the presence of substanceuse disorder. J Clin Psychiatry. 2007;68 Suppl 11:23-30.342. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversionof stimulants prescribed for ADHD: a systematic review of the literature. J Am AcadChild Adolesc Psychiatry. 2008 Jan;47(1):21-31.343. Chan E. The role of complementary and alternative medicine in attention-deficit hyperactivitydisorder. J Dev Behav Pediatr. 2002 Feb;23(1 Suppl):S37-S45.344. Complementary and Alternative Medicine. NIH 2009 February 5. Disponible en: URL: http://www.nlm.nih.gov/medlineplus/spanish/complementaryandalternativemedicine.html345. Coulter MK, Dean ME. Homeopathy for attention deficit/hyperactivity disorder or hyperkineticdisorder. Cochrane Database Syst Rev 2007;(4):CD005648.346. Weber W, Vander Stoep A, McCarty RL. Hypericum perforatum (St. John’s Wort) for Attention-230 CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
Deficit/Hyperactivity Disorder in Children and Adolescents. JAMA. 2008;229:2633-41.347. Pintov S, Hochman M, Livne A, Heyman E, Lahat E. Bach fl ower remedies used for attentiondeficit hyperactivity disorder in children--a prospective double blind controlled study.Eur J Paediatr Neurol. 2005;9:395-8.348. Jacobs J, Williams AL, Girard C, Njike VY, Katz D. Homeopathy for attention-deficit/hyperactivitydisorder: a pilot randomized-controlled trial. J Altern Complement Med. 2005Oct;11(5):799-806.349. Lamont J. Homeopathic treatment of attention deficit hyperactivity disorder: a controlledtrial. Br Homeopath J. 1997;86:196-200.350. Strauss LC. The effi cacy of a homeopathic preparation in the management of attention deficithyperactivity disorder. Biomedical Therapy. 2000;18(2):197-201.351. Frei H, Everts R, von Ammon K, Kaufmann F, Walther D, Hsu-Schmitz SF, et al. Homeopathictreatment of children with attention deficit hyperactivity disorder: a randomised, doubleblind, placebo controlled crossover trial. Eur J Pediatr. 2005 Dec;164(12):758-67.352. Loo SK. The EEG and ADHD. ADHD Rep. 2003;11:1-14.353. Nuñez G, Fernández Vidal J. Juego y psicomotricidad. Madrid: Cepe ed. 1994.354. Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case-control study of attentiondeficithyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy.J Am Acad Child Adolesc Psychiatry. 2002 Apr;41(4):378-85.355. Quintero Gutiérrez del Álamo FJ, Sansebastián J, García Álvarez R, Correas J, BarbudoE, Puente R, et al. Características clínicas del trastorno por défi cit de atención e hiperactividad(TDAH) en la infancia. En: Quintero Gutiérrez del Álamo FJ, Correas J, QuinteroLumbreras FJ, editores. Trastorno por Défi cit de Atención e Hiperactividad a lo largo de lavida. Madrid: Ergón; 2006. pp. 75-88.356. Código Civil Español. Art. 211. 2009.357. Ley 41/2002, de 14 de Noviembre, básica reguladora de la autonomía del paciente y dederechos y obligaciones en materia de información y documentación clínica. BOE núm. 274.2002.358. Código Civil Español. Arts. 154-163. 2009.359. Canadian Attention Deficit Hyperactivity Resource Alliance (CADDRA). Canadian ADHDpractice guidelines. 2007.360. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, et al. Evidence-based guidelinesfor management of attention-deficit/hyperactivity disorder in adolescents in transitionto adult services and in adults: recommendations from the British Association forPsychopharmacology. J Psychopharmacol. 2007 Jan;21(1):10-41.361. University of Michigan Health System. Guidelines for Clinical Care: Attention DeficitHyperactivity Disorder. 2005.CLINICAL PRACTICE GUIDELINES IN THE SPANISH NHS 231
Page 3 and 4:
Clinical Practice Guidelineon Atten
Page 5:
This CPG has been
Page 8 and 9:
AppendicesAppendix 1 Levels of evid
Page 10 and 11:
We trust that this work will undoub
Page 12 and 13:
Jesús Eirís Puñal, neuropaediatr
Page 15 and 16:
Questions to be answeredADHD1. How
Page 17 and 18:
39. In which ADHD subtypes is pharm
Page 19 and 20:
Recommendations of the CPG<
Page 21 and 22:
6. Assessment instruments6.1. Which
Page 23 and 24:
7.2.3. Pyschopedagogical re-educati
Page 25 and 26:
7.3.7. In ADHD: How long should the
Page 27 and 28:
7.3.13. What scientific evidence ex
Page 29 and 30:
B 7.5.3.2.In children and adolescen
Page 31 and 32:
9.4. How involved must the minor be
Page 33 and 34:
1. IntroductionBackgroundThe “Evi
Page 35 and 36:
Table 1. ADHD prevalence studies in
Page 37:
Health RepercussionsThe repercussio
Page 40 and 41:
Secondary objectivesa) To generate
Page 42 and 43:
• Formulation of clinical questio
Page 44 and 45:
evidence have been solved by consen
Page 46 and 47:
ment.At school age, the hyperactive
Page 48 and 49:
Volumetric brain studies have shown
Page 50 and 51:
4.4. What is the natural course of
Page 52 and 53:
Parents’ psychopathologyIn the st
Page 55 and 56:
5. DiagnosisQuestions to be answere
Page 57 and 58:
A SR conducted by the NICE guidelin
Page 59 and 60:
Family backgroundSummary of scienti
Page 61 and 62:
5.4. In the diagnosis of ADHD in ch
Page 63:
5.7. In the diagnosis of ADHD in ch
Page 66 and 67:
6.1. Which screening instruments an
Page 68 and 69:
Title Authors Year Description Age
Page 70 and 71:
Title Authors Year Description Age
Page 72 and 73:
RecommendationsC 6.1.1. 6.1.2. 6.2.
Page 74 and 75:
6.5. In ADHD in children and adoles
Page 77 and 78:
7. Treatment7.1. Psychological trea
Page 79 and 80:
Variable: ADHD symptomsScientific e
Page 81 and 82:
Variable: Internalized symptomsScie
Page 83 and 84:
The scientific evidence about the e
Page 85 and 86:
Variable: Social skillsScientific e
Page 87 and 88:
7.1.4. How effective is the psychol
Page 89 and 90:
7.2. Psychopedagogical TreatmentQue
Page 91 and 92:
• Working on habits that foster a
Page 93 and 94:
Teacher’s adaptationsScientific e
Page 95 and 96:
Scientific evidenceThere is not suf
Page 97 and 98:
7.3. Pharmacological treatmentQuest
Page 99 and 100:
to proteins is 15% and there are no
Page 101 and 102:
AtomoxetineThis is a non-stimulant
Page 103 and 104:
7.3.2. In ADHD: What pharmacologica
Page 105 and 106:
There is strong scientific evidence
Page 107 and 108:
Variable: Behavioural problemsScien
Page 109 and 110:
There is not sufficient scientific
Page 111 and 112:
BupropionThe NICE CPG</stro
Page 113 and 114:
Page 115 and 116:
Summary of the scientific evidence
Page 117 and 118:
7.3.4. In ADHD: When and with what
Page 119 and 120:
MethylphenidateSummary of the scien
Page 121 and 122:
AtomoxetineSummary of the scientifi
Page 123 and 124:
The consensus of the American Heart
Page 125 and 126:
In a RCT that studied the efficacy
Page 127 and 128:
7.3.13. What scientific evidence ex
Page 129 and 130:
7.3.15. Does the efficacy of pharma
Page 131 and 132:
Recommendations 7.3.17.1. 7.3.17.2.
Page 133 and 134:
Scientific evidenceThe scientific e
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
There is limited scientific evidenc
Page 141 and 142:
The combined intervention of MTA is
Page 143 and 144:
There is limited scientific evidenc
Page 145 and 146:
Page 147 and 148:
The scientific evidence of Zupancic
Page 149 and 150:
RecommendationsC 7.5.1.1.The use of
Page 151 and 152:
Summary of the scientific evidenceT
Page 153 and 154:
Summary of the scientific evidenceT
Page 155 and 156:
Elimination interventions include t
Page 157 and 158:
Auditory stimulationThis is based o
Page 159:
8. PreventionGiven the mainly genet
Page 162 and 163:
Recommendations 9.1.1.In the specif
Page 164 and 165:
Recommendations 9.4.1.Applicableleg
Page 166 and 167:
10. Diagnostic and therapeutic stra
Page 168 and 169:
Algorithm 3. Pharmacological treatm
Page 171 and 172:
11. Dissemination and implementatio
Page 173 and 174:
12. Future research recommendations
Page 175:
home, at school or in the recreatio
Page 178 and 179:
Appendix 1: Evidence levels and rec
Page 180 and 181:
Impulsivitya) Often blurts out answ
Page 182 and 183: Appendix 3. Information for patient
Page 184 and 185: 3. How does ADHD evolve with age?In
Page 186 and 187: 5.1. Psychological treatment for AD
Page 188 and 189: What drugs are available in Spain?A
Page 190 and 191: Is pharmacological treatment for AD
Page 192 and 193: 10. What can be done from school to
Page 194 and 195: Appendix 4. GlossaryAGREE: Instrume
Page 196 and 197: and mental operations, self-regulat
Page 198 and 199: tions that are to be compared.The r
Page 200 and 201: Appendix 5. AbbreviationsAACAPAAPAD
Page 202 and 203: MAMFF_20mgMHSMSCAMTA StudyNICENIMHN
Page 204 and 205: Appendix 6. Declaration of interest
Page 206 and 207: Alicia Koplowitz Foundation, Jansse
Page 208 and 209: Health Care Guideline: Diagnosis an
Page 210 and 211: Attention deficit hyperactivity dis
Page 212 and 213: tionario de Conners en nuestro medi
Page 214 and 215: 50. Quinn P, Wigal S. Perceptions o
Page 216 and 217: twin study: preliminary report. 199
Page 218 and 219: Number 3, August 1999. Agency for H
Page 220 and 221: controlled trial of integrated home
Page 222 and 223: Improvement. Clinical Practice Guid
Page 224 and 225: Adolesc Psychiatry. 2006 Nov;45(11)
Page 226 and 227: Acad Child Adolesc Psychiatry. 1995
Page 228 and 229: omized, double-blind, placebo-contr
Page 230 and 231: 300. Wilens TE, Newcorn JH, Kratoch
Page 234: P.V.P.: 10 €MINISTERIODE SANIDAD,
show all

CPG on ADHD

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?